FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 335:1682-1683 November 28, 1996 Number 22 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

A clinical diagnosis of diabetic nephropathy can be made in a patient with diabetes on the basis of persistent albuminuria (>300 mg per 24 hours), the presence of diabetic retinopathy, and the absence of any clinical or laboratory evidence of other kidney or renal tract disease.¹ This definition is valid in patients with either non-insulin-dependent diabetes mellitus (NIDDM) or insulin-dependent diabetes mellitus (IDDM).

Nephropathy is a major cause of morbidity and mortality in diabetes mellitus. Multiple factors contribute to the initiation and progression of diabetic nephropathy, including genetic and racial predisposition, glycemic and other metabolic abnormalities, alterations in systemic and . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Kjeldsen, S. E., Aksnes, T. A., Fagard, R. H., Mancia, G. (2009). CHAPTER 13 Hypertension. ESC Textbook of Cardiovascular Medicine 2: med-9780199566990-chapter-med-9780199566990-chapter [Abstract] [Full Text]  
• Authors/Task Force Members:, , Mancia, G., De Backer, G., Dominiczak, A., Cifkova, R., Fagard, R., Germano, G., Grassi, G., Heagerty, A. M., Kjeldsen, S. E., Laurent, S., Narkiewicz, K., Ruilope, L., Rynkiewicz, A., Schmieder, R. E., Struijker Boudier, H. A.J., Zanchetti, A., ESC Committee for Practice Guidelines (CPG):, , Vahanian, A., Camm, J., De Caterina, R., Dean, V., Dickstein, K., Filippatos, G., Funck-Brentano, C., Hellemans, I., Kristensen, S. D., McGregor, K., Sechtem, U., Silber, S., Tendera, M., Widimsky, P., Zamorano, J. L., ESH Scientific Council:, , Kjeldsen, S. E., Erdine, S., Narkiewicz, K., Kiowski, W., Agabiti-Rosei, E., Ambrosioni, E., Cifkova, R., Dominiczak, A., Fagard, R., Heagerty, A. M., Laurent, S., Lindholm, L. H., Mancia, G., Manolis, A., Nilsson, P. M., Redon, J., Schmieder, R. E., Struijker-Boudier, H. A.J., Viigimaa, M., Document Reviewers:, , Filippatos, G., Adamopoulos, S., Agabiti-Rosei, E., Ambrosioni, E., Bertomeu, V., Clement, D., Erdine, S., Farsang, C., Gaita, D., Kiowski, W., Lip, G., Mallion, J.-M., Manolis, A. J., Nilsson, P. M., O'Brien, E., Ponikowski, P., Redon, J., Ruschitzka, F., Tamargo, J., van Zwieten, P., Viigimaa, M., Waeber, B., Williams, B., Zamorano, J. L. (2007). 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 0: ehm236v1-75 [Full Text]  
• Parving, H.-H., Mogensen, C.E., Thomas, M.C., Brenner, B.M., Cooper, M.E., for the RENAAL study investigators, (2005). Poor prognosis in proteinuric type 2 diabetic patients with retinopathy: insights from the RENAAL study. QJM 98: 119-126 [Abstract] [Full Text]  
• Mizuno, S., Nakamura, T. (2004). Suppressions of chronic glomerular injuries and TGF-{beta}1 production by HGF in attenuation of murine diabetic nephropathy. Am. J. Physiol. Renal Physiol. 286: F134-F143 [Abstract] [Full Text]  
• Ruilope, L. M, Segura, J., Schiffrin, E. L (2003). Review: ACE inhibition or angiotensin receptor blockade: which should we use in diabetic patients?. Journal of Renin-Angiotensin-Aldosterone System 4: 74-79 [Abstract]  
• Parving, H.-H., Lehnert, H., Brochner-Mortensen, J., Gomis, R., Andersen, S., Arner, P., the Irbesartan in Patients with Type 2 Diabetes an, (2001). The Effect of Irbesartan on the Development of Diabetic Nephropathy in Patients with Type 2 Diabetes. NEJM 345: 870-878 [Abstract] [Full Text]